Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather H Cheng

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Cancer Immunology, Immunotherapy : CII|August 23, 2022
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinomaGuru P Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
JCO Precision Oncology|April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort StudyRuben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2014
Quantitative and stoichiometric analysis of the microRNA content of exosomesJohn R Chevillet, Qing Kang, Ingrid K Ruf, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 12, 2026
Prognostic Value of Cycle 1 SPECT SUV<sub>mean</sub> in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Ridvan A Demirci, Roman Gulati, et al.
Cancer Immunology, Immunotherapy : CII|August 23, 2022
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinomaGuru P Sonpavde, Benjamin Louis Maughan, Bradley Alexander McGregor, et al.
Cancer|January 30, 2026
Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot studyBruce Montgomery, Julie A Lynch, Jessica Brown, et al.
JCO Precision Oncology|April 25, 2024
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to <sup>177</sup>Lu-PSMA-617: A Retrospective Multicenter Cohort StudyRuben Raychaudhuri, George Mo, Abuzar Moradi Tuchayi, et al.
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2014
Quantitative and stoichiometric analysis of the microRNA content of exosomesJohn R Chevillet, Qing Kang, Ingrid K Ruf, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Pageof 15